Christopher J. Logothetis

About Christopher J. Logothetis

Despite initial response, most prostate cancers will invariably become resistant to available therapies. Therefore, it is essential to understand these mechanisms of resistance operating in tumor cells as this will not only inform current drug treatment modalities but also future medication design. Dr. Logothetis and his team of experts propose to explore the resistance mechanisms for the recently FDA-approved medication, Zytiga (abiraterone acetate). Zytiga functions by inhibiting the synthesis of tumor-associated androgen, the male hormone testosterone, which plays a critical role in prostate cancer survival and metastasis. This team will study the androgen receptor signaling pathway in detail to understand the mechanisms that mediate resistance to therapy.
Potential patient benefit: This team’s work will help us understand the reasons for the failure of medications in castration-resistant prostate cancer (CRPC) patients and provide valuable data for the future design of new and better therapies for CRPC patients.

Christopher J. Logothetis, MD –

The University of Texas MD Anderson Cancer Center Mechanisms of Resistance to Androgen Biosynthesis Inhibition in Castration-Resistant Prostate Cancer Bone Metastases

Co-investigators:

Gary Gallick, PhD; Sankar Maity, PhD; Randall Millikan, MD, PhD; Mark Bedford, PhD; Eleni Efstathiou, MD, PhD